Physician profile
Boris Kobrinsky
NPI 1295789600
$1,187.90
in general payments reported to CMS, 2019-2025
22 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $88.22 · 2021: $77.66 · 2022: $40.28 · 2023: $48.66 · 2024: $572 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.93 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $207.59 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Janssen Biotech, INC. | $175.78 | 2019-2024 | Tecvayli, Imbruvica, Darzalex |
| Merck Sharp & Dohme LLC | $141.28 | 2019-2025 | Keytruda, Lynparza |
| Pfizer INC. | $112.33 | 2019-2025 | |
| Taiho Oncology, INC. | $96.38 | 2021-2024 | |
| Eisai INC. | $59.15 | 2024 | |
| Mirati Therapeutics, INC. | $44.06 | 2023-2024 | Krazati |
| Astrazeneca Pharmaceuticals LP | $41.17 | 2024 | Lynparza, Enhertu |
| Amgen INC. | $40.30 | 2019-2024 | Evenity, Prolia |
| Seagen INC. | $25.15 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.53 | 2024 | |
| Genmab U.S., INC. | $24.00 | 2024 | Tivdak |
| E.R. Squibb & Sons, L.L.C. | $23.20 | 2025 | Eliquis |
| Stemline Therapeutics INC. | $22.98 | 2024 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $22.54 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $22.34 | 2024 | |
| Epizyme, INC. | $20.81 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.47 | 2024 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $19.47 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.80 | 2019 | |
| Puma Biotechnology, INC. | $15.65 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Kobrinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.